Ryvu Therapeutics - Diversified pipeline ensures continued newsflow
In our March 2020 report, we highlighted that Ryvu, now a pure-play biotech with a diversified R&D pipeline, is funded into 2021, which...
92 Views
Ryvu Therapeutics - Successful Phase I with SEL24/MEN1703
In March 2020, Ryvu announced its partner Menarini Group (via subsidiary Berlin-Chemie) has successfully completed the dose-escalation part (Phase...
470 Views
Ryvu Therapeutics - First ever clinical data from lead assets in 2020
Ryvu Therapeutics (formerly Selvita) is now trading as a standalone biotech after its drug discovery services business was spun out in October...
1.5k Views
Ryvu Therapeutics - Introducing Ryvu Therapeutics
The corporate split is now complete and Selvita is continuing as Ryvu Therapeutics, which will focus on innovative drug development. The contract...
937 Views
Selvita - Progress across pipeline; Services sales up 53%
Over the past several months Selvita has been executing on its new R&D-focused multi-year strategy funded by the share issue in March 2018...
56 Views
No more insights